Financials data is unavailable for this security.
View more
Year on year Zhejiang Jiuzhou Pharmaceutical Co Ltd had relatively flat revenues (5.45bn to 5.52bn), though the company grew net income 12.20% from 920.92m to 1.03bn. A reduction in the cost of goods sold as a percentage of sales from 66.41% to 63.74% was a component in the net income growth despite flat revenues.
| Gross margin | 32.61% |
|---|---|
| Net profit margin | 14.25% |
| Operating margin | 17.04% |
| Return on assets | 6.28% |
|---|---|
| Return on equity | 8.23% |
| Return on investment | 7.67% |
More ▼
Cash flow in CNYView more
In 2023, Zhejiang Jiuzhou Pharmaceutical Co Ltd increased its cash reserves by 364.13%, or 2.41bn. Cash Flow from Financing totalled 2.10bn or 38.06% of revenues. In addition the company generated 1.36bn in cash from operations while cash used for investing totalled 1.06bn.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 9.51 |
|---|---|
| Tangible book value per share | 8.76 |
More ▼
Balance sheet in CNYView more
| Current ratio | 3.65 |
|---|---|
| Quick ratio | 2.48 |
| Total debt/total equity | 0.1009 |
|---|---|
| Total debt/total capital | 0.0909 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 25.00% and 4.50%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is above the industry average.
| Div yield(5 year avg) | 0.90% |
|---|---|
| Div growth rate (5 year) | 20.11% |
| Payout ratio (TTM) | 64.14% |
| EPS growth(5 years) | 42.85 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -40.42 |
More ▼
